|
||||||||||||||
 |
||||||||||||||
|
|
JACI Highlights - June 2009Fluticasone furoate nasal spray reduces eye symptoms in allergic rhinitis by an indirect neural mechanismBothersome eye symptoms occur frequently in patients with nasal allergies. Most people think that the eye symptoms result from pollen deposition in the eye; fluticasone furoate nasal spray (FFNS), however, reduces eye symptoms. To explain this paradox, Baroody et al. proposed that pollen landing in the nose initiates a nasal ocular reflex and ocular symptoms. Repetitive pollen exposure during the season increases nasal inflammation and augments this neural reflex. FFNS reduces nasal inflammation and decreases the reflex and ocular symptoms. The authors tested this hypothesis by performing nasal allergen challenge with grass or ragweed in 20 allergic subjects on 3 consecutive days to mimic the allergy season. Each subject was pretreated with either placebo or FFNS prior to these challenges and then crossed over to the other treatment. With the subjects on placebo, inflammation in the nose occurred and nasal and eye symptoms got progressively worse. Treatment with FFNS reduced inflammation and nasal and eye symptoms. These results, published in the June 2009 issue of The Journal of Allergy and Clinical Immunology, confirm that eye symptoms can occur as a result of allergen deposition in the nose and show that FFNS reduced nasal inflammation and subsequent eye symptoms. Thus, the reduction of ocular symptoms by FFNS during the season suggests that a significant proportion of ocular symptoms occur by an indirect neural mechanism initiated by allergen deposition in the nose.
|
||||||||||||
|
© 1996-2009 · All Rights Reserved · American Academy of Allergy Asthma & Immunology |
||||||||||||||
